<DOC>
	<DOCNO>NCT02583594</DOCNO>
	<brief_summary>Primary Objective : - To characterize pharmacodynamic profile 2 treatment course alemtuzumab administer subcutaneous injection 2 treatment course alemtuzumab administer intravenous infusion patient progressive multiple sclerosis . Secondary Objectives : - To characterize pharmacokinetic profile alemtuzumab administer subcutaneous injection intravenous infusion patient progressive multiple sclerosis . - To characterize safety tolerability alemtuzumab administer subcutaneous injection intravenous infusion patient progressive multiple sclerosis .</brief_summary>
	<brief_title>A Study Characterize Subcutaneous Intravenous Alemtuzumab Patients With Progressive Multiple Sclerosis</brief_title>
	<detailed_description>The duration study per patient approximately 25 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<mesh_term>Dexchlorpheniramine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Male female adult diagnosis Multiple Sclerosis ( MS ) base 2010 revision McDonald criterion . Diagnosis progressive MS include primary progressive MS secondary progressive MS. Age ≥18 year . Signed informed consent form . Covered health insurance system applicable , and/or compliance recommendation national law force relate biomedical research . Not administrative legal supervision . Exclusion criterion : Patients relapse remit MS. Any prior treatment alemtuzumab antiCD52 antibody . Treatment natalizumab 4 month prior Study Visit 1 . Progressive multifocal leukoencephalopathy ( PML ) , clinical imaging sign possibly indicative undiagnosed PML . Particular vigilance need patient prior natalizumab exposure , even last exposure 4 month prior Study Visit 1 . Treatment methotrexate , azathioprine , cyclosporine past 6 month . Treatment mitoxantrone , cyclophosphamide , cladribine , rituximab , immunosuppressant cytotoxic therapy ( steroid ) last 12 month , determine treat physician residual immune suppression treatment . Treatment glatiramer acetate interferon beta past 4 week . Treatment fingolimod within past 2 month . Treatment dimethyl fumarate past 4 week . Treatment teriflunomide within past 12 month unless patient complete accelerated clearance cholestyramine activate charcoal . Any known contraindication symptomatic therapy use infusion management guidance study . Hypersensitivity contraindication acyclovir . History hypersensitivity reaction localize injection site reaction biological molecule . If female , pregnancy ( define positive βHCG blood test ) lactate breastfeed . Current participation another investigational interventional study . Any significant change chronic treatment medication ( ie , new chronic medication ) within 14 day inclusion . An investigational medicinal product within 3 month 5 halflives , whichever longer , study inclusion . Total lymphocyte CD3+ count normal limit screen . If abnormal cell count ( ) return within normal limit , eligibility may reassess . Live , attenuate vaccine within 3 month prior randomization ( Day 1 ) visit , varicellazoster , oral polio , rubella vaccine . Any clinically relevant finding physical examination , medical history , laboratory assessment would compromise safety patient . Women childbearing potential protect highlyeffective method ( ) birth control and/or unwilling unable test pregnancy . Latent active tuberculosis infection , verify test per local practice . Infection human immunodeficiency virus ( HIV ) . Known Hepatitis B ( HBV ) Hepatitis C ( HCV ) infection . Active infection , eg , deep tissue infection , Investigator consider sufficiently serious preclude study participation . Prior history invasive fungal infection . Any patient , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . Any patient exclusion period previous study accord applicable regulation . Any patient contact case emergency . Any patient Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>